化学療法誘発性末梢神経障害治療の世界市場レポート 2025年

化学療法誘発性末梢神経障害治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.9％で25億米ドルに成長します。予測期間の成長は、標的療法開発、神経保護剤、統合ケアパス、患者中心のケアモデル、規制支援に起因します。予測期間の主な動向には、新規薬剤製剤、非薬理学的介入、神経可塑性に基づく治療、長期生存支援、認知行動療法などが含まれます。

化学療法誘発性末梢神経障害治療市場の成長軌道は、がんの有病率の増加によって牽引されると予測されます。がんは、体内での異常細胞の無秩序な増殖と拡散を特徴とし、しばしば化学療法による治療が必要となります。しかし、特定の化学療法薬の潜在的な副作用のひとつに、化学療法誘発性末梢神経障害（CIPN）があります。世界のがん罹患率の上昇は、化学療法誘発性末梢神経障害治療市場の拡大に大きく寄与すると予想されています。例えば、2023年1月に米国がん協会が発表した報告書によると、米国では女性の肝臓がんと新たに診断される症例が増加しており、2022年の12,660症例から2023年には13,230症例に増加しています。このがん症例の増加は、化学療法誘発性末梢神経障害治療市場の成長を促進する触媒として作用します。

化学療法誘発性末梢神経障害治療市場の拡大は、ヘルスケア支出の増加によってもたらされています。ヘルスケア支出とは、特定の地域や国のヘルスケア部門に割り当てられる総財源を指し、化学療法誘発性末梢神経障害（CIPN）の治療を支援するために不可欠です。この資金は、特定のがん治療によって引き起こされる神経学的副作用を緩和・管理し、化学療法を受けている患者や化学療法から回復している患者の幸福を確保することを目的としています。たとえば、2023 年 5 月に英国政府機関である国家統計局が発表した報告書によると、英国の医療費は 2022 年から 2023 年にかけて 5.6%増加しましたが、2022年の成長率は 0.9% でした。2023年の英国のヘルスケア支出は約3,176億3,000万米ドル（2,920億英ポンド）でした。この医療費の増加は、今後の化学療法誘発性末梢神経障害治療市場の成長の触媒として作用します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の化学療法誘発性末梢神経障害治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の化学療法誘発性末梢神経障害治療市場：成長率分析
• 世界の化学療法誘発性末梢神経障害治療市場の実績：規模と成長, 2019-2024
• 世界の化学療法誘発性末梢神経障害治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の化学療法誘発性末梢神経障害治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の化学療法誘発性末梢神経障害治療市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経保護療法
• 抗炎症療法
• 神経伝達物質に基づく療法
• 抗酸化物質
• その他の薬物クラス
• 世界の化学療法誘発性末梢神経障害治療市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 治療
• その他の治療法
• 世界の化学療法誘発性末梢神経障害治療市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド
• ジェネリック
• 世界の化学療法誘発性末梢神経障害治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の化学療法誘発性末梢神経障害治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 調査機関
• 専門クリニック
• 世界の化学療法誘発性末梢神経障害治療市場、タイプ別サブセグメンテーション：神経保護療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビタミンB複合体
• アルファリポ酸
• アセチル-L-カルニチン
• 世界の化学療法誘発性末梢神経障害治療市場、タイプ別サブセグメンテーション：抗炎症療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 非ステロイド性抗炎症薬（NSAID）
• 世界の化学療法誘発性末梢神経障害治療市場、タイプ別サブセグメンテーション：神経伝達物質療法、実績と予測, 2019-2024, 2024-2029F, 2034F
• ガバペンチン
• プレガバリン
• デュロキセチン
• 世界の化学療法誘発性末梢神経障害治療市場、タイプ別サブセグメンテーション：抗酸化物質、実績と予測, 2019-2024, 2024-2029F, 2034F
• N-アセチルシステイン
• グルタチオン
• コエンザイムQ10
• 世界の化学療法誘発性末梢神経障害治療市場、タイプ別サブセグメンテーション：その他の薬物クラス、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所治療
• オピオイド
• ハーブ療法

第7章 地域別・国別分析

• 世界の化学療法誘発性末梢神経障害治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の化学療法誘発性末梢神経障害治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 化学療法誘発性末梢神経障害治療市場：競合情勢
• 化学療法誘発性末梢神経障害治療市場：企業プロファイル
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Midatech Pharma PLC Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Lee's Pharmaceutical Holdings Limited Overview, Products and Services, Strategy and Financial Analysis
  • RELIEF THERAPEUTICS Holding SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eurofins Advinus
• WEX Pharmaceuticals Inc.
• Asahi Kasei Corporation
• MediciNova Inc.
• Solasia Pharma K.K.
• ESTEVE
• ChromaDex Inc.
• Apollo Endosurgery Inc.
• REGENACY PHARMACEUTICALS INC.
• Novaremed AG
• MAKScientific LLC
• Sova Pharmaceuticals Inc.
• Kineta Inc.
• Aptinyx Inc.
• Apexian Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 化学療法誘発性末梢神経障害治療市場2029：新たな機会を提供する国
• 化学療法誘発性末梢神経障害治療市場2029：新たな機会を提供するセグメント
• 化学療法誘発性末梢神経障害治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chemotherapy Induced Peripheral Neuropathy (CIPN) encompasses a range of symptoms and complications arising from specific chemotherapy drugs utilized in cancer treatment. It represents a form of peripheral neuropathy, involving impairment or dysfunction of the nerves connecting the brain and spinal cord to the body.

The primary drug categories for CIPN treatment include nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidants, and others. Nerve protective therapy aims to preserve nerve health and function, crucial in managing chemotherapy-induced peripheral neuropathy for symptom relief. Treatment modalities encompass medications, therapies, and other interventions, with both branded and generic drugs available. These CIPN treatment drugs are distributed through hospital pharmacies, retail outlets, online platforms, and other channels, catering to end-users such as hospitals, research institutes, and specialty clinics.

The chemotherapy induced peripheral neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy induced peripheral neuropathy treatment market statistics, including the chemotherapy induced peripheral neuropathy treatment industry's global market size, regional shares, competitors with an chemotherapy induced peripheral neuropathy treatment market share, detailed chemotherapy induced peripheral neuropathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy induced peripheral neuropathy treatment industry. This chemotherapy induced peripheral neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.66 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to chemotherapy advancements, cancer treatment expansion, limited treatment options, increased cancer incidences, neurological research

The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.5 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to targeted therapies development, neuroprotective agents, integrated care pathways, patient-centered care models, regulatory support. Major trends in the forecast period include novel drug formulations, non-pharmacological interventions, neuroplasticity-based therapies, long-term survivorship support, cognitive behavioral therapies.

The growth trajectory of the chemotherapy-induced peripheral neuropathy treatment market is anticipated to be driven by the increasing prevalence of cancer. Cancer, characterized by the unregulated proliferation and dissemination of abnormal cells within the body, often necessitates chemotherapy treatment. However, one of the potential side effects of certain chemotherapy drugs is chemotherapy-induced peripheral neuropathy (CIPN). The rising incidence of cancer cases globally is expected to contribute significantly to the expansion of the chemotherapy-induced peripheral neuropathy treatment market. For instance, a report by the American Cancer Society in January 2023 revealed an increase in newly diagnosed cases of liver cancer in females in the United States, rising from 12,660 cases in 2022 to 13,230 cases in 2023. This escalation in cancer cases acts as a catalyst propelling the growth of the chemotherapy-induced peripheral neuropathy treatment market.

The expansion of the chemotherapy-induced peripheral neuropathy treatment market is being driven by an increase in healthcare spending. Healthcare spending, which refers to the total financial resources allocated to the healthcare sector in a specific region or country, is essential for supporting treatments for chemotherapy-induced peripheral neuropathy (CIPN). This funding aims to alleviate and manage the adverse neurological effects caused by certain cancer therapies, ensuring the well-being of patients undergoing and recovering from chemotherapy. For example, in May 2023, a report from the Office for National Statistics, a UK government department, indicated that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth of 0.9% in 2022. The UK's healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. This increase in healthcare expenditure acts as a catalyst for the growth of the chemotherapy-induced peripheral neuropathy treatment market in the future.

Product innovation emerges as a prominent trend in the chemotherapy-induced peripheral neuropathy treatment market, with major market players prioritizing the development of novel products to enhance efficacy and consolidate their market position. Notably, in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, announced the FDA's approval of their Investigational New Drug Application (IND) for ATX01, a Phase 2 first-in-class candidate designed for individuals with erythromelalgia. The ATX01 for the Pain of Chemotherapy (ACT) study targeting chemotherapy-induced peripheral neuropathy (CIPN) has commenced randomized patient enrollment. Both programs have secured fast-track designation from the FDA, signifying their potential significance in addressing unmet medical needs.

Technological advancements, particularly the incorporation of quell technology, are a focal point for major companies in the chemotherapy-induced peripheral neuropathy treatment market as they endeavor to fortify their market standing. For instance, in January 2022, NeuroMetrix Inc., a US-based provider of non-invasive medical devices, attained breakthrough device designation from the U.S. Food and Drug Administration (FDA) for the mitigation of moderate to severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) persisting for at least 6 months post-chemotherapy completion. This designation marks a pivotal milestone for NeuroMetrix's efforts to introduce Quell technology to alleviate the distressing effects experienced by individuals grappling with CIPN.

In August 2024, Pharmacosmos Group, an international healthcare company based in Denmark, acquired G1 Therapeutics for $405 million. The purpose of this acquisition is to expand and accelerate the availability of COSELA(R) (trilaciclib), a treatment aimed at reducing chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). G1 Therapeutics is a US-based biopharmaceutical company that specializes in developing and commercializing small molecule therapeutics for cancer treatment.

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market include Hoffmann-La Roche Ltd., Midatech Pharma PLC, Novartis AG, Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, Eurofins Advinus, WEX Pharmaceuticals Inc., Asahi Kasei Corporation, MediciNova Inc., Solasia Pharma K.K., ESTEVE, ChromaDex Inc., Apollo Endosurgery Inc., REGENACY PHARMACEUTICALS INC., Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., WinSanTor Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2024. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chemotherapy induced peripheral neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy induced peripheral neuropathy treatment market consists of sales of pharmaceutical drugs prescribed to alleviate chemotherapy-induced peripheral neuropathy symptoms. These drugs include pain relievers, antidepressants, anticonvulsants, and topical creams. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chemotherapy induced peripheral neuropathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chemotherapy induced peripheral neuropathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chemotherapy induced peripheral neuropathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Nerve Protective Therapy; Anti-Inflammatory Therapy; Neurotransmitter Based Therapy; Antioxidant; Other Drug Classes
• 2) By Treatment: Medication; Therapy; Other Treatments
• 3) By Drug Type: Branded; Generic
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Research Institutes; Specialty Clinics
• Subsegments:
• 1) By Nerve Protective Therapy: Vitamin B Complex; Alpha-Lipoic Acid; Acetyl-L-Carnitine
• 2) By Anti-Inflammatory Therapy: Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 3) By Neurotransmitter Based Therapy: Gabapentin; Pregabalin; Duloxetine
• 4) By Antioxidant: N-acetylcysteine; Glutathione; Coenzyme Q10
• 5) By Other Drug Classes: Topical Treatments; Opioids; Herbal Remedies
• Companies Mentioned: Hoffmann-La Roche Ltd.; Midatech Pharma PLC; Novartis AG; Lee's Pharmaceutical Holdings Limited; RELIEF THERAPEUTICS Holding SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Characteristics

3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies

4. Chemotherapy Induced Peripheral Neuropathy Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Growth Rate Analysis
• 5.4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Total Addressable Market (TAM)

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation

• 6.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nerve Protective Therapy
• Anti-Inflammatory Therapy
• Neurotransmitter Based Therapy
• Antioxidant
• Other Drug Classes
• 6.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Therapy
• Other Treatments
• 6.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded
• Generic
• 6.4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Specialty Clinics
• 6.6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Nerve Protective Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin B Complex
• Alpha-Lipoic Acid
• Acetyl-L-Carnitine
• 6.7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Anti-Inflammatory Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Neurotransmitter Based Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gabapentin
• Pregabalin
• Duloxetine
• 6.9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Antioxidant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• N-acetylcysteine
• Glutathione
• Coenzyme Q10
• 6.10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Treatments
• Opioids
• Herbal Remedies

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional And Country Analysis

• 7.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 8.1. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 9.1. China Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 9.2. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 10.1. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 11.1. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 11.2. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 12.1. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 13.1. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 14.1. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 14.2. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 15.1. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 15.2. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 16.1. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 17.1. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 18.1. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 19.1. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 20.1. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 21.1. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 21.2. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 22.1. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 23.1. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 23.2. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 24.1. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 24.2. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 25.1. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 25.2. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 26.1. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 26.2. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 27.1. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 28.1. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 28.2. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 29.1. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
• 29.2. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape
• 30.2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Company Profiles
  • 30.2.1. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Midatech Pharma PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lee's Pharmaceutical Holdings Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. RELIEF THERAPEUTICS Holding SA Overview, Products and Services, Strategy and Financial Analysis

31. Chemotherapy Induced Peripheral Neuropathy Treatment Market Other Major And Innovative Companies

• 31.1. Eurofins Advinus
• 31.2. WEX Pharmaceuticals Inc.
• 31.3. Asahi Kasei Corporation
• 31.4. MediciNova Inc.
• 31.5. Solasia Pharma K.K.
• 31.6. ESTEVE
• 31.7. ChromaDex Inc.
• 31.8. Apollo Endosurgery Inc.
• 31.9. REGENACY PHARMACEUTICALS INC.
• 31.10. Novaremed AG
• 31.11. MAKScientific LLC
• 31.12. Sova Pharmaceuticals Inc.
• 31.13. Kineta Inc.
• 31.14. Aptinyx Inc.
• 31.15. Apexian Pharmaceuticals Inc.

32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

34. Recent Developments In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

35. Chemotherapy Induced Peripheral Neuropathy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer